Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors. Curr Oncol Rep 2024 Nov;26(11):1530-1542
Date
10/28/2024Pubmed ID
39466478Pubmed Central ID
PMC11776107DOI
10.1007/s11912-024-01610-wScopus ID
2-s2.0-85207815177 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
PURPOSE OF REVIEW: This study aims to present the current landscape of immunotherapy in the management of small bowel neuroendocrine tumors and identify ongoing and future targets for improved response.
RECENT FINDINGS: Somatostatin analogs and mTOR inhibitors remain cornerstones of non-surgical treatment, and applications of PRRT in SBNET are promising. Several efforts to replicate the success of immunotherapies in other solid tumors have been attempted in SBNET, with limited responses observed with current immune targets, such as PD-1/PD-L1 and CTLA-4. Epigenetic analyses have suggested a potential role for methylation and histone acetylation in SBNET tumorigenesis that warrant greater exploration. While the incidence of SBNET continues to increase, the number of effective therapies is few. Further elucidation of targetable components of the SBNET immune microenvironment with greater modulatory effects is necessary to improve outcomes in this growing patient population.
Author List
Fields BC, Ayabe RI, Seo YD, Maxwell JE, Halperin DMAuthor
Yongwoo Seo MD Assistant Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansImmunotherapy
Intestinal Neoplasms
Intestine, Small
Neuroendocrine Tumors
Tumor Microenvironment
